Neuropsychopharmacology
May 24, 2018
Oliver Vranjkovic, Garrett Winkler, Danny G Winder
Forced abstinence from chronic two bottle-choice ethanol drinking produces the development of negative affective states in female C57BL/6J mice. We previously reported that this disrupted behavior is acutely reversed by administration of ketamine 30 min-prior to testing. Here we assessed whether ketamine can be used as an inoculant against the development of abstinence- dependent affective...
F1000Research
May 24, 2018
Ronald S. Duman
203 citations
Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has...
Cureus
May 18, 2018
Yasar Sattar, John M Wilson, Ali M Khan et al.
The biochemical processes involved in depression go beyond serotonin, norepinephrine, and dopamine. The N-methyl-D-aspartate (NMDA) receptor has a major role in the neurophysiology of depression. Ketamine, one of the prototypical NMDA antagonists, works rapidly in controlling depressive symptoms, including acutely suicidal behavior, by just a single injection. Ketamine may rapidly increase the...
Human Psychopharmacology: Clinical and Experimental
May 2018
Minling Zhang, Hongbo He, Yuping Ning et al.
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and...
CNS Drugs
May 2018
Patricio Molero, J A Ramos-Quiroga, Rocío Martín‐Santos et al.
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes continued blockade of the glutamate N-methyl-D-aspartate (NMDA) receptor, though this might not primarily mediate the antidepressant effect. Alternative hypotheses include selectivity for the NMDA receptor subtype...
Molecular medicine reports
May 1, 2018
Yonglai Zhang, Rui Sha, Kaiguo Wang et al.
26 citations
Tetrahydropalmatine exerts numerous pharmacological activities, including analgesic and narcotic effects; anti-arrhythmic, blood pressure lowering and cardioprotective effects; protective effects against cerebral ischemia-reperfusion injury; inhibition of platelet aggregation; prevention of ulcerative diseases and inhibition of gastric acid secretion; antitumor effects; and beneficial effects...
Journal watch
April 23, 2018
Joel Yager
Intravenous ketamine reduces symptoms of depression and suicidality for up to several weeks, but less is known about the non–FDA-approved intranasal
International Journal of Environmental Research and Public Health
April 17, 2018
Carola Rong, Caroline Park, Joshua D. Rosenblat et al.
116 citations
OBJECTIVES: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to...
Frontiers in Behavioral Neuroscience
April 16, 2018
André Schwertner, Maxciel Zortéa, Felipe Vasconcelos Torres et al.
48 citations
Ketamine is a non-competitive N-Methyl-D-Aspartate (NMDA) receptor antagonist whose effect in subanesthetic doses has been studied for chronic pain and mood disorders treatment. It has been proposed that ketamine could change the perception of nociceptive stimuli by modulating the cortical connectivity and altering the top-down mechanisms that control conscious pain perception. As this is a...
British Journal of Anaesthesia
April 13, 2018
Phillip E. Vlisides, Tarik Bel‐bahar, Amanda Nelson et al.
117 citations
BackgroundDespite its designation as a 'dissociative anaesthetic,' the dissociative and psychoactive effects of ketamine remain incompletely understood. The goal of this study was to characterise the subjective experiences and accompanying EEG changes with subanaesthetic doses of ketamine.MethodsHigh-density EEG was recorded in 15 human volunteers before, during, and after subanaesthetic...